TherapeuticsMD Inc (NASDAQ:TXMD) — Market Cap & Net Worth
Market Cap & Net Worth: TherapeuticsMD Inc (TXMD)
TherapeuticsMD Inc (NASDAQ:TXMD) has a market capitalization of $23.96 Million ($23.96 Million) as of May 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #24475 globally and #5022 in its home market, demonstrating a -5.05% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying TherapeuticsMD Inc's stock price $2.07 by its total outstanding shares 11574362 (11.57 Million). Analyse TherapeuticsMD Inc cash conversion from operations to see how efficiently the company converts income to cash.
TherapeuticsMD Inc Market Cap History: 2015 to 2026
TherapeuticsMD Inc's market capitalization history from 2015 to 2026. Data shows change from $6.00 Billion to $23.96 Million (-37.80% CAGR).
Index Memberships
TherapeuticsMD Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.41 Trillion | 0.00% | #707 of 976 |
|
NASDAQ Composite
IXIC
|
$38.77 Trillion | 0.00% | #2337 of 3165 |
Weight: TherapeuticsMD Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
TherapeuticsMD Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how TherapeuticsMD Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
5.65x
TherapeuticsMD Inc's market cap is 5.65 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $6.00 Billion | $20.14 Million | -$85.08 Million | 297.94x | N/A |
| 2016 | $3.34 Billion | $19.36 Million | -$89.88 Million | 172.51x | N/A |
| 2017 | $3.50 Billion | $16.78 Million | -$76.93 Million | 208.34x | N/A |
| 2018 | $2.20 Billion | $16.10 Million | -$132.62 Million | 136.96x | N/A |
| 2019 | $1.40 Billion | $49.65 Million | -$176.15 Million | 28.21x | N/A |
| 2020 | $700.25 Million | $64.87 Million | -$183.52 Million | 10.79x | N/A |
| 2021 | $205.73 Million | $2.57 Million | -$172.41 Million | 79.96x | N/A |
| 2022 | $64.70 Million | $69.96 Million | $112.00 Million | 0.92x | 0.58x |
| 2023 | $26.04 Million | $1.30 Million | -$10.28 Million | 20.00x | N/A |
| 2024 | $9.95 Million | $1.76 Million | -$2.18 Million | 5.65x | N/A |
Competitor Companies of TXMD by Market Capitalization
Companies near TherapeuticsMD Inc in the global market cap rankings as of May 4, 2026.
Key companies related to TherapeuticsMD Inc by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #499 globally with a market cap of $52.60 Billion USD.
- Zoetis Inc (NYSE:ZTS): Ranked #525 globally with a market cap of $50.31 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #526 globally with a market cap of $50.29 Billion USD ( CN¥343.70 Billion CNY).
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #572 globally with a market cap of $45.88 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #499 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #525 | Zoetis Inc | NYSE:ZTS | $50.31 Billion | $114.16 |
| #526 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $50.29 Billion | CN¥53.88 |
| #572 | GALDERMA GROUP AG | NYSE:GALDY | $45.88 Billion | $42.15 |
TherapeuticsMD Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, TherapeuticsMD Inc's market cap moved from $6.00 Billion to $ 23.96 Million, with a yearly change of -37.80%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $23.96 Million | +26.99% |
| 2025 | $18.87 Million | +89.53% |
| 2024 | $9.95 Million | -61.78% |
| 2023 | $26.04 Million | -59.75% |
| 2022 | $64.70 Million | -68.55% |
| 2021 | $205.73 Million | -70.62% |
| 2020 | $700.25 Million | -50.00% |
| 2019 | $1.40 Billion | -36.48% |
| 2018 | $2.20 Billion | -36.92% |
| 2017 | $3.50 Billion | +4.68% |
| 2016 | $3.34 Billion | -44.36% |
| 2015 | $6.00 Billion | -- |
End of Day Market Cap According to Different Sources
On May 4th, 2026 the market cap of TherapeuticsMD Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $23.96 Million USD |
| MoneyControl | $23.96 Million USD |
| MarketWatch | $23.96 Million USD |
| marketcap.company | $23.96 Million USD |
| Reuters | $23.96 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About TherapeuticsMD Inc
TherapeuticsMD, Inc. operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors an… Read more